Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
Data from a Phase 3 study revealed that ivonescimab demonstrates a statistically significant and clinically meaningful improvement in progression-free survival compared to pembrolizumab for patients with PD-L1-positive advanced non-small cell lung cancer.
The results were presented today at the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer.
The HARMONi-2 study randomised 398 patients from 55 centers in China to receive either ivonescimab (20 mg/kg) or pembrolizumab (200 mg) every three weeks.
To be eligible for the trial, patients had to have untreated locally advanced or metastatic NSCLC, ECOG PS 0-1, PD-L1 positive (TPS ≥1%) but negative EGFR mutations or ALK rearrangements.
At the planned interim analysis, ivonescimab demonstrated a median PFS of 11.14 months, significantly longer than the 5.82 months observed with pembrolizumab.
This represents a 49% reduction in the risk of progression or death (stratified hazard ratio [HR], 0.51; 95% CI, 0.38 to 0.69; p<0.0001).
According to Dr. Caicun Zhou, Shanghai Pulmonary Hospital in Shanghai, China, the benefit of ivonescimab was consistent across various patient subgroups, including those with squamous and non-squamous NSCLC, different levels of PD-L1 expression, and those with liver or brain metastases.
Dr. Zhou reported that safety profiles for both treatments were comparable, with no new safety signals identified for ivonescimab.
Treatment-related serious adverse events (TRSAEs) occurred in 20.8% of patients receiving ivonescimab and 16.1% of those receiving pembrolizumab.
Grade ≥3 immune-related adverse events were also similar between the two groups. In patients with squamous cell carcinoma, grade 3 or higher-treatment related adverse events were comparable between two groups.
“The findings from the HARMONi-2 study support the use of ivonescimab as a promising first-line treatment option for patients with PD-L1-positive advanced NSCLC, potentially offering a new and effective choice for managing this challenging disease,” he said.
“These results highlight ivonescimab's potential as a new standard of care.”
Source: International Association for the Study of Lung Cancer
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.